Poland’s Mabion Gets €30m R&D Loan
Hopes To Be Among The First EU Firms With Biosimilar Rituximab
After receiving a €30m loan from the European Investment Bank, Mabion believes it could be among the first EU-based companies to introduce biosimilar rituximab into the European market.
You may also be interested in...
Amgen has received its fourth US biosimilar approval for its Avsola infliximab rival to Janssen’s Remicade.
As the US generics market continues to experience turbulence, the industry’s largest players are adopting a wide range of strategies to cope with the uncertainty as signs of stabilization begin to emerge.
The AAM has welcomed reports that US negotiators for the proposed US-Mexico-Canada trade agreement could be willing to soften demands on intellectual-property protections for pharmaceuticals, including the data exclusivity period for biologics.